The Post-Patent Revolution in Obesity Treatment
Maximizing Global Health and economic Gains with Affordable GLP-1 / GIP Agents
The Problem: The Profound Toll of Obesity on Healthy Ageing
Obesity is a global epidemic that severely compromises both healthspan and lifespan (Whitlock 2009, Kitahara 2014, Jia 2022). Moderate obesity (BMI 30–35) reduces life expectancy by approximately 3 years, and severe obesity (BMI 40–50) by up to 10 years, which is comparable to lifelong smoking. It is a primary driver of chronic disease such as Type 2 diabetes and cardiovascular disease, and significantly shortens healthspan. The direct annual healthcare cost of obesity in the U.S. alone is between $170 billion and $260 billion.
The Solution: A New Class of Agents could Halve Obesity Rates
New medications, including agonists targeting GLP-1, GIP, and the glucagon receptor, are revolutionary, consistently achieving 15%–20% average weight loss. Beyond weight loss, these agents improve metabolic and cardiovascular outcomes, with potential benefits in addiction and dementia, reinforcing their description as “the everything drugs“. Widespread global access to these drugs could save between 2.1 million and 3.9 million lives per year among patients with diabetes and/or obesity.
In the UK, availability of these drugs at a cost of £16.5 billion a year could halve adult obesity in England by 2030. However, this cost equates to almost the entire annual NHS prescribing budget.
Source: Adult obesity rate from Health Survey for England 2022, Nesta modelling
The Economic Opportunity: The ‘$6 Revolution’
Brand-name prices currently exceed $1,000 per month in the U.S., posing a huge budget challenge. However, this dynamic is poised to shift dramatically as patents expire in global markets like India and China. This transition, dubbed the ‘$6 Revolution,’ is projected to enable manufacturers to produce biosimilars for less than $6 per month. Since the treatments are cost-effective over a lifetime, this generic shift will maximize societal value.
A 75% price decline due to competition will enable prevention at a marginal cost, resulting in massive, long-term economic savings for health systems through reduced chronic disease and increased productivity.
The transition of this revolutionary drug class from patent protection to generic availability marks an inflection point that could redefine global public health, offering an affordable path to save millions of lives.